Cargando…
P986: COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS
Autores principales: | Zaroogian, Zachary, Adamczyk, Elżbieta, Moszyńska, Adrianna, Obacz, Marta, Pakulska, Urszula, Durham, Benjamin, Mazan, Milena, Mowla, Shoron, Wnęk, Katarzyna, Somasundara, Amritha Varshini Hanasoge, Barczuk, Beata, Gołas, Aniela, Levine, Ross, Rzymski, Tomasz, Rampal, Raajit K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431548/ http://dx.doi.org/10.1097/01.HS9.0000970848.13342.8d |
Ejemplares similares
-
JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
por: McKenney, Anna Sophia, et al.
Publicado: (2018) -
Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019) -
Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges
por: Ajufo, Helen O., et al.
Publicado: (2023) -
Atypical Presentation of Erythroid/Megakaryocytic Leukemic Transformation of a Myeloproliferative Neoplasm Associated with Mutation and Loss of TP53
por: Chernak, Brian J., et al.
Publicado: (2020) -
Parity-induced changes to mammary epithelial cells control NKT cell expansion and mammary oncogenesis
por: Somasundara, Amritha Varshini Hanasoge, et al.
Publicado: (2021)